Satellite Meeting -Intern. Conference on HHV-6 & 7

[Guest guest]

http://www.hhv-6conference.com/pdfs/HHV6SatBroch08.pdf

International Symposium on Viruses

In CHRONIC FATIGUE SYNDROME & POST-VIRAL FATIGUE

June 22 & 23, 2008

Baltimore, land, USA

A satellite meeting of the 6th

International Conference on HHV-6 & 7

HHV-6 FOUNDATION

IACFS/ME

````````````````````

Dear Friends,

It gives me great pleasure to invite you to the

inaugural Viruses In CFS satellite conference, which

will follow immediately after the end of the 6th

International Conference on HHV-6 & 7 on June 22nd

through Monday, June 23rd.

There is increasing evidence of an infectious etiology

in a subset of CFS patients, most often with viral

agents. The sudden onset of CFS in some patients

with an " infectious-like " illness, the nature of some

of the symptoms, the state of chronic immune

activation, and prospective epidemiologic studies

demonstrating incident cases of CFS developing

following several well-characterized and documented

infectious illnesses have made plausible the

possibility that the illness can be triggered and

perpetuated by an infectious agent, at least in some

patients with CFS.

For this reason, we are sponsoring this special

satellite conference reviewing current information on

the role of viral infectious agents in chronic fatigue

syndrome.

This satellite conference would not have been

possible if the HHV-6 Foundation had not initiated

the suggestion. I would also like to thank Dharam

Ablashi and Loomis for their expertise and

advice in organizing this program, as well as the

IACFS, the HHV-6 Foundation Scientific Advisory

Board and staff, and the generous conference

sponsors for their support.

Sincerely,

Komaroff

Symposium Co-Chair

``````````````````

SPONSORS OF THE SYMPOSIUM

1) THE HHV-6 Foundation

ABOUT THE HHV-6 Foundation

The HHV-6 Foundation is a non-profit entity formed

in 2004 to encourage scientific exchange among

scientists and to provide pilot grants for promising

scientific and clinical research. An important mission

of the Foundation is to disseminate new knowledge

about this virus. The Foundation helps to research

the disease associations that have been suggested

for HHV-6. The Foundation is proud to organize and

sponsor this conference and to support the dedicated

virologists and clinicians who have worked so hard to

bring clarity to the nature of viruses and their role in

chronic fatigue syndrome.

Loomis, President & Executive Director

Dharam Ablashi, VP & Scientific Director

Hischier, VP

Jill Chase, Project Manager

Mona Eliassen, Chairman, Board of Directors

2) IACFS/ME

ABOUT THE IACFS

The mission of the IACFS/ME, a non-profit

organization, is to promote, stimulate and coordinate

the exchange of ideas related to CFS, ME, and

fibromyalgia (FM) research, patient care and

treatment. In addition, the IACFS/ME periodically

reviews the current research and treatment literature

and media reports for the benefit of scientists,

clinicians and patients. The IACFS/ME also conducts

and/or participates in local, national, and

international scientific conferences in order to

promote and evaluate new research and to

encourage future research ventures and cooperative

activities to advance scientific and clinical knowledge

of these illnesses.

Klimas, MD, President

Birgitta Evengard, MD, PhD, Vice-President

Leonard , PhD, Vice-President

Lucinda Bateman, MD, Secretary

Fred Friedberg, PhD, Treasurer

````````````````````

TARGET AUDIENCE:

Clinicians and scientists who study the role of

viruses in chronic fatigue, post-infective fatigue, and

CNS dysfunction. The satellite symposium on Viral

Infections in CFS provides you with opportunities to

network with the participants and speakers to

discuss the latest advances and issues on the

molecular biology and pathogenesis of these viruses,

and to share the latest news and views on diagnosis,

antiviral therapy, and prophylaxis of these infections.

SATELLITE CONFERENCE TOPICS:

* Clinician forum on antiviral therapies

* HHV-6 in CFS

* Other Viruses in CFS

* Borna virus in CFS

* EBV in CFS

* Parvovirus B-19 in CFS

* Retrovirus K-18 activation

* Enterovirus

* Post viral fatigue

CONFERENCE CO-CHAIRS:

* Komaroff (USA)

* Lloyd (AUSTRALIA)

PROGRAM COMMITTEES:

* Dharam Ablashi (USA)

* Chia (USA)

* Jonthan Kerr (UK)

* Komaroff (USA)

* Lloyd (Australia)

* G. Montoya (USA)

PRIMARY SPONSORS:

* The HHV-6 Foundation

* IACFS/ME

CO-SPONSORS:

* THE CFIDS Association

* Whittemore Institute

* Epiphany Biosciences

* Angel Donors

Speaker Topics

HHV-6 & CFS

Komaroff MD Overview on HHV-6 & CFS

Kazuhiro Kondo MD, PhD Identification of novel

HHV-6 neurovirulent latent protein that causes mood

disorders in CFS, psychosis and HHV-6

encephalopathy G. Montoya MD Antiviral

treatment of CFS patients with elevated antibodies

to HHV-6 & EBV

Chronic EBV and CFS

Barbara Savoldo MD Chronic EBV, fatigue and

immunotherpay by cytotoxic T-cell lymphocyte

infusion Marshall PhD EBV DUTPase in CFS

and sickness behavior Brigitte Huber PhD EBV and

interferon activation of retrovirus K-18 in CFS

Enterovirus and CFS

Nora Chapman PhD Overview of enterovirus

infections and diagnostic testing Chia MD E

nterovirus infections in CFS

Parvovirus and CFS

Mariko Seishima MD Elevated Parvovirus antibodies

and complement in CFS

Borna virus and CFS

Liv Bode PhD Human Borna virus infections: a

possible role in chronic fatigue syndrome? Keizo

Tomonaga DVM, PhD Borna Virus antibodies in CFS

patients vs. controls

Immunological markers and infection in CFS

Klimas MD Immune markers in viral illness and

CFS

Post-Viral Fatigue: prospective studies

White MD Overview on Post-Viral Fatigue

Lloyd MD Post-viral fatigue after acute

infections Ute Vollmer-Conna BSc PhD UNSW

Cytokines in Post-viral fatigue

Microarray studies

Jonthan Kerr MD, PhD Gene expression subtypes in

patients with CFS and ME Suzanne Vernon PhD Host

genetics and viral infection

Twin Studies on viruses in CFS

Birgitta Evengard MD, PhD Viral markers in Swedish

twins discordant for CFS

Clinician Forum : treating CFS patients with antivirals

Dan MD - Antiviral treatment of patients

with HHV-6, EBV & Enterovirus: Case reports

Kenny De Meirleir MD, Ph.D - RNaseL activity:

correlation to viral infection in CFS and viral

infections

Marin Lerner, MD - EBV & CMV in CFS and

cardiomyopath

Symposium Speakers

HHV-6 & CFS

G. Montoya, MD, Stanford University, USA

Dr. Montoya is Associate Professor of Medicine and

Associate Chief for Clinical Affairs for the Division of

Infectious Diseases at Stanford University School of

Medicine, Director of the Toxoplasmosis Serology

Laboratory and Director of the Immunocompromised

Host Service at Stanford Medical Center. He is new to

the CFS field, but made news recently with his Roche

sponsored placebo controlled trial of valganciclovir in

a subset of CFS patients with elevated titers to

HHV-6 and EBV. Montoya initiated the trial after he

found that several CFS patients with exceptionally

high antibody titers to HHV-6 & EBV responded very

well to antiviral treatment, with full remissions. He

hopes to announce the preliminary results of this

trial at the conference.

Komaroff, MD, Harvard Medical School,

Boston, USA

Dr. Komaroff is the Simcox-Clifford-Higby professor of

medicine at Harvard Medical School (HMS), and

editor-inchief of Harvard Health Publications at HMS.

Komaroff was director of the Division of General

Medicine at Brigham and Women's Hospital for 15

years. One of the earliest physician investigators to

study Chronic Fatigue Syndrome, Komaroff has been

a member of the CFS Coordinating Committee of the

U.S. Department of Health and Human Services. One

of the first to report HHV-6 reactivation in chronic

fatigue syndrome, Dr. Komaroff's research has found

immunological, neuroimaging and neurocognitive

deficits in CFS patients that cannot be explained by

concurrent depression. His epidemiological research

also has helped to establish the point prevalence of

CFS in adults living in the U.S.

Kazuhiro Kondo, MD, PhD, Jikei University School of

Medicine, Tokyo

Kazuhiro Kondo is Professor and Chairman of the

Department of Virology at the Jikei University School

of Medicine in Tokyo. He is internationally recognized

as one of the top experts on HHV-6 molecular

biology. His research focuses on the role of HHV-6 in

latency associated genes and the role of HHV-6 & 7

in CFS and other states of fatigue. In a recent study

he found that HHV-6 and HHV-7 reactivation in the

saliva can be used as objective biomarkers for

fatigue. His latest work involves the identification of

a novel HHV-6 neurovirulent latent protein that he

can cause mood disorders in CFS, psychosis and

HHV-6 encephalopathy.

Chronic EBV and CFS

Marshall , PhD, Ohio State University , USA

A specialist in microbiology and immunology, Dr.

and his associate Ron Glaser have

published ground-breaking research on how stress

modulates now the immune system and herpesvirus

reactivation, and certain viral enzymes affect normal

cellular metabolism and herpesvirus replication. They

discovered that the EBV-encoded dUTPase induces

the increased expression of pro-inflammatory

cytokines and IL-10 from human macrophages and

that mice injected with dUTPase develop sickness

behavior in the absence of viral replication. They

hope to develop drugs based upon the action of the

dUTPase which may be useful in cancer and viral

chemotherapy.

Brigitte Huber, PhD, Tufts University, Boston, USA

Brigitte Huber studied immunogenetics at University

of London and is currently a Professor of Pathology

at Tufts University. She is currently studying the

presence of retrovirus HERV K-18 as marker for those

who might develop CFS after an acute infection such

as mononucleosis. Her research shows that EBV

induces the HERV K-18 envelope gene to trigger the

expression of a specific superantigen and that there

are more HERV K-18 alleles in post-mono CFS

patients than in controls. She hopes to identify other

subsets among CFS patients.

Barbara Savoldo MD , Baylor College of Medicine,

Houston,USA

Dr. Savoldo has authored or co-authored over 20

papers on EBV immunotherapy in EBV associated

lymphoproliferative disorders and the use of

cytotoxic T cell lymphocyte infusion to restore the

EBV-specific EBV related T cell responses. She and

her associates at Baylor College of Medicine have

recently completed a trial of autologous EBV specific

CTLs for patients with severe chronic EBV and will

report on those findings. Severe chronic EBV was

defined in their trial as patients with elevated EBV

DNA (over 4,000 copies per ml in the peripheral

blood) and free EBV DNA in the serum or spinal fluid.

An earlier trial completed in 2002 was successful.

Enterovirus and CFS

Nora Chapman, PhD, University of Nebraska, Omaha,

USA

Dr. Chapman studies persistent coxsackievirus

infections in murine models of chronic myocarditis

and dilated cardiomyopathy. She has demonstrated

that the expression of viral proteins in the heart

generate significant impairment of cardiomyocyte

function and promote the generation of dilated

cardiomyopathy. She and her associates at University

of Nebraska became interested in the role of

enterovirus in CFS after working with Dr. Chia

who found enterovirus infections in the gut biopsies

of CFS patients, by staining slides of gut tissues

using antigen specific monoclonal antibodies.

Chia, MD, UCLA School of Medicine & EV Med

Research, California, USA

Dr. Chia is President of EV Med Research and

Assistant Clinical Professor at UCLA School of

Medicine. An infectious disease specialist by training,

Chia became interested in the role of enterovirus in

Chronic Fatigue Syndrome and recently published

original research from a study that found 135 out of

165 (82%) of CFS patients had stomach biopsy

samples that stained positive for enterovirus

antigens compared with 7/34 or 20% of the controls.

He also found that 9/24 or 37% of CFS patients had

enterovirus RNA in their gut tissue compared to 1 of

21 controls. Dr. Chia is actively investigating

treatment strategies for persistent enterovirus

infections.

Parvovirus and CFS

Mariko Seishima, MD, Ogaki Municipal Hospital

Mariko Seishima is a dermatologist who has

investigated the underlying cause of various

dermatological disorders. Seishima recently studied

patients who developed chronic fatigue after a

Parvovirus B-19 infection and found that 3 out of 210

developed persistent symptoms. Although Parvovirus

DNA and IgM antibodies disappeared from the sera,

his group found that complement levels were lower

in those who developed CFS than those who did not.

Dirk Lassner, PhD, of the Charité -

Universitätsmedizin Berlin

A pathologist, Lassner will describe his group's

fascinating finding that in over 1600 endomyocardial

biopsies, the most common virus found was

parvovirus B-19, followed by HHV-6. All of these

cardiomyopathy patients have persistent fatigue. He

raises the question: could a subset of CFS patients

in fact have subclinical viral myocarditis?

Borna virus and CFS

Liv Bode, PhD, Koch Institute, Berlin,

Germany

Dr. Bode, PhD, permanent scientist at the

Koch Institute and lecturer in virology and infectious

diseases at the Free University of Berlin, has

authored or co-authored over 45 papers on Borna

virus (BDV) infection in both animals and in human

psychiatric disease including chronic fatigue. She

contributed to high-ranking priority publications on

BDV target cells in blood, isolation of human virus,

and antiviral therapy (amantadine), the latter shown

to be effective both in vitro against human and

equine isolates, and in vivo in depressed patients in

open trials. Borna virus does not circulate in the

blood. Therefore, she and her associates developed

sensitive methods to detect the virus activity

through circulating immune complexes, antigenemia

and free antibodies. Since the diagnosis of Borna

virus in humans is controversial, the findings in

human disease have been a matter of scientific and

even political debate, recently leading to Dr. Bode's

Whistleblower award from the Association of German

Scientists (VDW)l. Studies in Japan and more

recently, in China have demonstrated higher levels of

antibodies in patients with CFS than in controls,

supporting the suggestion by Bode and her

associates that Borna virus plays a role in human

neurological disease.

Keizo Tomonaga, DVM, PhD, Osaka University, Japan

Dr. Tomonaga has published over 30 papers on Borna

virus (BDV). Once thought to be exclusively an

animal virus important to horses, this neurotropic

virus has now been implicated in human psychiatric

disease and chronic fatigue syndrome. Dr. Tomonaga

has studied the mechanisms by which Borna virus

persists in the brain. He and his associate Kazuyoshi

Ikuta have found Borna virus antibodies and Borna

virus RNA in the families of CFS patients at higher

levels than in controls. Tomonaga has also

demonstrated that BDV infection impairs astrocyte

function which results in reduced inflammatory

response and persistent infection.

Imunolog ical markers and infection in CFS

Klimas, MD, University of Miami, USA

Dr. Klimas is the President of the International

Association for Chronic Fatigue Syndrome/ME, the

organization of researchers and clinicians dedicated

to furthering our knowledge of this disabling illness.

She is a Professor of Medicine, Psychology,

Microbiology and Immunology at the University of

Miami School of Medicine. Dr Klimas directs the

UM/VAMC Gulf War and Chronic Fatigue Syndrome

Research Center. Her interests include studying the

interaction between inflammation, immune function

and the neuroendocrine system in CFS and GWI and

has found a number of immune function

abnormalities including a defect in NK cell activity.

She has also identified a subgroup of CFS patients

characterized by impaired natural immunity and

cognitive dysfunction. She also studies gene

expression before, during and after an exercise

challenge in GWI and CFS.

Post-Viral Fatigue: prospective studies

White, MD, Queen School of Medicine,

London, UK

White is a Professor of Psychological Medicine

at the Wolfson Institute of Preventive Medicine. He

was an early leader in efforts to learn more about

post-viral fatigue and the reason why some patients

with acute mononucleosis develop chronic fatigue

syndrome, while others are unaffected.

Lloyd, MD, UNSW School of Medical Sciences

Dr. Lloyd is Associate Professor of the Inflammation

Research Unit at the University of New South Wales

in Australia. An infectious disease specialist and

immunologist, he put together an important

CDC-funded prospective study of several hundred

patients who developed acute illnesses such as

mononucleosis and then followed them over time to

determine the percentage that went on to develop

Chronic Fatigue Syndrome. He found that roughly

11% of patients who suffer from acute infections of

mononucleosis, Q Fever and Ross River fever

ultimately go on to develop CFS or post viral fatigue.

He has since used these samples to determine that

eight key cytokines were not significantly different in

the CFS patients compared to those who recovered.

He has also gleaned valuable information from this

study on the genes that are differentially expressed

in post viral fatigue.

Ute Vollmer-Conna, PhD, UNSW School of Psychiatry

Dr. Vollmer-Conna is a psychoneuroimmunologist

who has authored or co-authored over a dozen

studies on the pathophysiology of post-infective and

chronic fatigue. She works with Lloyd and a

multidisciplinary team of scientists and clinicians on

the Dubbo Infective Outcomes Study. Her most

recent paper reported a comprehensive analysis of

the longitudinal production profiles of eight

cytokines, which failed to reveal substantive

differences between controls and patients with

post-viral fatigue. Microa rray stu dies

Kerr, MD, PhD, St. 's University of

London, UK

A senior lecturer in inflammation & microbiology, Dr.

Kerr also runs a CFS research program funded by two

CFS charities in the UK. His interest in CFS began

during a study of the parvovirus B-19 infection when

he realized that a percentage of cases developed

CFS and persisted for several years. His interest in

Chronic Fatigue Syndrome (CFS) began during a study

of the consequences of parvovirus B19 infection,

when he showed that a percentage of infected cases

developed CFS which persisted for several years He

has recently reported 88 human genes whose

dysregulation is associated with CFS, and which can

be used to derive genomic CFS subtypes which have

marked differences in clinical phenotype and

severity.

Suzanne Vernon, PhD, CFIDS Association of America,

USA

Suzanne D. Vernon, Ph.D. joined the staff of the

a CFIDS Association as Scientific Director in November

a2007. Dr. Vernon began her scientific career in 1990

aat the Centers for Disease Control and Prevention

a(CDC) in Atlanta, Georgia where since 1997 she led

athe CDCs CFS laboratory team. More than half of her

a75 peer-reviewed scientific publications deal with

aCFS genomics and pathophysiology. In her new

acapacity as Scientific Director, Dr. Vernon leads the

aAssociation's expanded research program which

aincludes developing priorities to achieve expedited

aprogress for therapeutic interventions and cure,

abuilding collaborative networks worldwide, and

aserving as the Association's scientific expert in

anumerous settings

New twin study on viruses in CFS

Birgitta Evengard, MD, PhD, Umea University, Umea,

Sweden

Dr. Evengard is head of the Department of Infectious

Disease at Umea University in Sweden. She previous

position was adjunct professor at the Dept Clinical

Microbiology at the Karolinska Institute in Stockholm,

Sweden. She has published several important studies

on fatigue in the context of pathogens. A specialist

in infectious diseases and clinical immunology, Dr.

Evengard has studied the epidemiology of fatigue in

a large study of over 12,000 Swedish twin pairs and

found an incidence which was higher than expected

and that both environmental and genetic factors

were important in chronic fatigue syndrome. In a

recent study she found increased levels of Candida

albicans in the fecal microflora of chronic fatigue

syndrome patients during the acute phase of their

illness. Dr. Evengard will include new data on a study

of viral markers and cytokines in Swedish twin pairs

discordant for CFS in her talk.

Clinician Forum: treating CFS pat ients with

antivirals Panel discusion

Dan , MD, Sierra Nevada Internal Medicine,

Incline Village, USA

Dr. is a clinician and CFS expert who

documented a CFS outbreak in Nevada in 1985 and

who was, along with his partner Cheney, among

the first to suggest that viruses such as HHV-6 and

EBV might be involved in the Chronic Fatigue

Syndrome and co-authored several important papers

describing the neurological dysfunction and NK cell

deficits found in cases that broke out in Nevada in

the late 1980's. was one of the first to

conduct a trial of an antiviral/immunomodulator drug,

(Ampligen) for CFS patients. He is also the Medical

Director of the Whittemore Institute for

Neuroimmune Disease in Reno, Nevada.

Kenny De Meirleir, MD, PhD, Himmunitas

Foundation, Belgium

A prominent clinician/researcher in CFS/ME, Kenny

runs a large clinic for CFS/ME patients in Brussels,

Belgium. He is also professor of Physiology,

Pathophysiology and Medicine at the Vrije

Universiteit Brussel and clinical professor at the

University of Nevada Medical School in Reno. Kenny

has published award winning studies on exercise

physiology in CFS.

Kenny has published many research papers on

chronic fatigue syndrome issues on topics such as

intracellular immune dysfunction, mitochondrial

disorders, joint hypermobility, and impairment of the

2-5A synthetase/RNase L pathway in chronic fatigue

syndrome patients. He has also been a leader in the

use of antiviral and immunomodulating treatments

such as Ampligen, Kutapressin (Nexavir) and

herb/vitamin combinations known to have

antiviral/immune boosting qualities.

Lerner, MD, Beaumont Hospital,

Michigan, USA

The former Director of Infectious Diseases at Wayne

State University School of Medicine, Dr. Lerner has

published over 10 papers since 1993 on the role of

subclinical myocarditis in a subset of CFS patients.

He has also reported success with long courses of

antiviral therapy in patients with chronic EBV and

CMV infections. Dr. Lerner uses antibody tests for

early antigen to CMV and EBV that are not available

in most commercial laboratories; he believes that

they are better for differentiating active from latent

infections. Although these papers received very little

attention in the past, there has been interest in the

tie between viral myocarditis and CFS recently since

a series of three papers from Germany have found

HHV-6 and parvovirus B-19 to be the most common

viruses found in biopsies of patients with viral

myocarditis. Both viruses are also implicated in CFS.

About Symposium on Viruses in Chronic

Fatigue Syndrome

WHO SHOULD ATTEND

We encourage research scientists and clinicians,

health care workers and providers interested in

Chronic Fatigue Syndrome to attend.

MAIN CONFERENCE

The symposium is a satellite conference held just

after the 6th International Conference on HHV-6 & 7

to be held June 19-22nd.

Satellite Conference Schedule

The Satellite Conference will begin with lunch at

12:30pm on June 22nd, immediately following the

main conference. The first session begins at 2:00pm.

The last session on June 23rd ends at 3:30pm and

there will be informal discussions until 5:00pm.

REGISTRATION INFORMATION

We prefer online registration at

www.hhv-6conference.com/ satellite. Forms are

provided in this packet if you would like to fax or

mail your registration. Registration fees for the

satellite conference attendees include the Program

and Conference Book and lunch on Monday, June

23rd. Note that if you are attending the Viruses In

CFS satellite conference only (and are NOT

registering for the HHV-6 & 7 conference), you may

attend the June 22nd HHV-6 & 7 Conference session

on HHV-6 and neurological disease.

SATELLITE CONFERENCE FEES

Satellite Conference on Viruses in CFS, June 22 - 23

(includes dinner Sunday and lunch Sunday and

Monday)

For those attending the main conference, the

incremental cost is: $125

For those attending the Viruses in CFS conference

only:

* Non-profit rate: $220

* Standard/Corporate Rate: $285

Conference Fee Cancellation Policy

We will grant a 100% refund up until May 20th. A

50% penalty is charged for cancellation within 30

days and no refund will be granted for cancellation

made within seven days of the conference.

Cancellations must be written and can be received by

either fax, 1- or email,

gwyneth_ramirez@HHV- 6foundation.org. It is

acceptable to substitute another individual. The

Foundation must guarantee meeting space and

catering minimum.

HOTEL

The hotel is just 10 minutes from

Baltimore-Washington International Airport, and an

hour from Dulles International and Reagan airports.

Area attractions include:

* land Science Center/IMAX theatre

* 1st Mariner Arena

* Fort McHenry

* Baltimore Museum of Art/Walters Art Gallery

* Oriole Park at Camden Yards

* Baltimore Inner Harbor

* University of land at Baltimore

* National Aquarium at Baltimore

* s Hopkins University

HOTEL RATES:

The discounted conference hotel room price is $189

for standard/ double occupancy. Students: Note that

up to four people can stay per room for the same

price. To reserve a hotel room, you may either call

the Baltimore Hyatt or register on the hotel website,

www.baltimore.hyatt. com. Please use code G-HHV6.

HYATT HOTEL

CANCELLATION POLICY

The Hyatt is able to offer a reduced rate only

because the Foundation guaranteed a minimum room

block. Therefore, the Hyatt is not able to offer a

complete refund on hotel reservations. Before May

20th, you may cancel your room with no charge. After

May 20th, two nights will be charged and this

amount will not be refundable. After June 6th, no

refunds will be made. Although we negotiated a

room block, we are only intermediaries and requests

for refunds for rooms booked must be directed to the

hotel.

``````````````````````````````

Important Dates and deadlines

Early conference registration

deadline: May 20, 2008

Hotel discount rate deadline: May

20, 2008

Cancellation for a full refund: May

20, 2008

Cancellation for a 50% refund:

June 6, 2008

Please note that due to contractual

arrangements, these cut-off dates

are non-negotiable.

``````````````````````````````

Register by May 20th to receive the hotel room

rate guarantee!

Please complete this form and fax, email or mail

back to the Foundation.

Fax: 1-

email: gwyneth_ramirez@...

Or mail to: Gwyneth , HHV-6 Foundation, 277

San Ysidro Road, Santa Barbara, CA 93108, USA

CONTACT INFORMATION:

Salutation: Dr. Mr. Mrs. Ms. First Name Last Name

Nickname (for badge)

Degree Title/Position Department Institution

Street Address City State/Province Zip/Postal Code

Country

Email Address Phone (office) Phone (mobile)

````````````````````````

CONFERENCE RATES (includes a special dinner

Sunday night and lunch Monday):

Non-Profit/Academic Rate: $220

Corporate/Regular Rate: $285

Price for those attending main conference on HHV-6

& 7 (June 19-22): $125

HOTEL ACCOMODATIONS:

Please contact the Hyatt Regency Hotel directly to

reserve a room for your conference attendance. A

guaranteed rate of $189 is available to conference

attendees if the reservation is made before May

20th. After May 20th the standard hotel rates will

apply. The conference code is G-HHV6.

The Hyatt Regency Baltimore, 300 Light Street,

Baltimore, MD 21202

Website: www.baltimore.hyatt.com Phone: +1 410

528 1234

OPTIONAL: ACCOMPANYING PERSON

Please note that dinner Sunday night and lunch on

Sunday and Monday are available to accompanying

persons for an additional cost of $100 per person.

Name of accompanying person(s)

Total conference fees: $ ---

* Check enclosed. Make check payable to the HHV-6

Foundation International Conference in US dollars.

Please include registrant's name on the check and

return this form with payment. If you need to send a

check in a foreign currency, please add a fee of $25

US to cover processing fees.

* Please charge my credit card. * Visa * MasterCard

* American Express Name as it appears on credit

card Signature Billing address Credit Card Number

Expiration date